Associations of reproductive hormones with serum uric acid and hyperuricemia in PCOS
Correlation analyses revealed that the SUA level was negatively associated with the FSH level (
r = − 0.09,
P < 0.001) and was positively associated with the testosterone level (
r = 0.16,
P < 0.001) (Table
2). Accordingly, FSH was negatively associated with hyperuricemia (OR = 0.89, 95% CI = 0.83–0.95,
P < 0.001), and testosterone was positively associated with hyperuricemia (OR = 1.75, 95% CI = 1.45–2.11,
P < 0.001) (Table
3). After adjusting for age, BMI and eGFR, there was still a positive correlation between the SUA and testosterone levels (
r = 0.16,
P < 0.001) (Table
2). In addition, both LH/FSH (OR = 1.20, 95% CI = 1.01–1.43,
P = 0.04) and the testosterone level (OR = 1.56, 95% CI = 1.27–1.90,
P < 0.001) were positively associated with hyperuricemia in the adjusted model (Table
3).
Table 2
Correlations between reproductive hormones and serum uric acid
FSH | −0.09 | < 0.001 | −0.03 | 0.17 |
LH | −0.03 | 0.16 | 0.004 | 0.88 |
LH/FSH | 0.01 | 0.75 | 0.005 | 0.84 |
E2 | −0.01 | 0.59 | − 0.01 | 0.55 |
T | 0.16 | < 0.001 | 0.11 | < 0.001 |
Table 3
Associations between reproductive hormones and hyperuricemia in PCOS
Hormones | OR (95%CI) |
P
| OR (95%CI) |
P
|
FSH | 0.89 (0.83–0.95) | < 0.001 | 0.94 (0.88–1.01) | 0.91 |
LH | 1.00 (0.98–1.03) | 0.94 | 1.02 (0.99–1.05) | 0.14 |
LH/FSH | 1.14 (0.97–1.35) | 0.11 | 1.20 (1.01–1.43) | 0.04 |
E2 | 1.00 (1.00–1.00) | 0.94 | 1.00 (1.00–1.00) | 0.97 |
T | 1.75 (1.45–2.11) | < 0.001 | 1.56 (1.27–1.90) | < 0.001 |
Discussion
In the present study, we found that both the serum uric acid level and prevalence of hyperuricemia increased in the age- and BMI-stratified PCOS population. In addition, a high level of testosterone was strongly associated with an elevated SUA level and the prevalence of hyperuricemia. To our knowledge, this study is the first to report the prevalence of hyperuricemia in such a large sample size of women with PCOS.
Previous studies analyzing the SUA level in PCOS are scarce and have yielded controversial results. Quinonez et al. and Yarali et al. found that the SUA concentration was significantly increased in women with PCOS [
16,
17]. However, Anttila et al. and Manuel et al. reported that no differences in uric acid levels were detected between women with PCOS and control women [
14,
15]. We hypothesize that the two main reasons for these conflicting results may be the small sample size and the BMI. The numbers of women with PCOS in these studies ranged from thirty to fifty-five. Therefore, the results from these studies may be greatly affected by the heterogeneity of PCOS. Due to the influence of obesity on the SUA level [
3,
22], the different rates of obesity among the PCOS and control populations influenced these results. Therefore, we used age- and BMI-stratified analyses to further exemplify the contribution of these two key factors on the SUA level. Our present results found that the SUA level and prevalence of hyperuricemia increased greatly in both the PCOS and non-PCOS groups as BMI increased. Overall, 58.75% of women with obesity and PCOS had hyperuricemia, which was nearly threefold higher than that in women with PCOS and a normal BMI. In addition, we found that both the SUA level and the prevalence of hyperuricemia were similar in the age-stratified PCOS group. These findings indicated that elevated SUA levels in PCOS might be independent of age and BMI.
Apart from the effect of obesity on SUA level, sex hormones also play a significant part in uric acid regulation. It was found that the uric acid level varied across the menstrual cycle in healthy premenopausal women, with the highest level in the follicular phase and a decrease during the luteal phase [
7]. E
2 was inversely associated with the uric acid level [
7,
23]. E
2 may affect the serum levels of uric acid through mechanisms potentially including renal clearance, secretion and reabsorption [
5,
6]. However, we did not find a correlation between E
2 and the SUA level in PCOS. One study reported that FSH was positively associated with the uric acid concentration [
7]; on the contrary, another study found a low concentration of FSH in women with gout, although it did not find a direct association between FSH and the uric acid level [
24]. In our study, the negative correlation between FSH and SUA disappeared when we adjusted for age and BMI, which indicated that this association was not independent. Interestingly, we observed a positive association between LH/FSH and hyperuricemia. Thus, further mechanistic study is warranted to clarify these inconsistent findings.
Androgen excess is a common characteristic in PCOS and promotes metabolic disorders [
25]. Androgens might also influence uric acid metabolism to some extent. Higher SUA concentrations in men compared with women supported a possible correlation between androgen and uric acid [
26]. It was observed that free testosterone was positively associated with uric acid concentration in healthy female population [
27]. Plasma metabolomics analysis found that PCOS with hyperandrogenism had higher uric acid level than PCOS with anovulation and polycystic ovaries [
18]. Our results also confirmed that testosterone was positively correlated with SUA level and hyperuricemia independently of age and BMI. In women with PCOS, Diane
35 treatments were associated with a decrease in uric acid levels, which was in parallel to the decrease in the free androgen index [
15]. Animal experiments showed that androgens might increase serum uric acid levels by inducing the hepatic metabolism of purine nucleotides [
28,
29] and enhancing purine turnover in the kidney [
30]. These findings indicated that purine metabolism might be the target of hormonal action, although more mechanistic studies are needed to confirm this hypothesis.
Whether SUA is a cause or a risk factor, we suggest that more attention should be devoted to women with high levels of SUA, especially infertile women with obesity or/and hyperandrogenism, because uric acid is a purine derivative and purines might inhibit oocyte maturation [
31,
32]. Previous evidence had demonstrated that hyperuricaemia identifies women at increased risk of adverse maternal and fetal outcome [
33]. Hyperuricemia is a common finding in preeclamptic pregnancies [
34]. Uric acid impacts on placental development and function and maternal vascular health through promoting inflammation, oxidative stress and endothelial dysfunction [
35]. Hyperuricemia may be a pathogenic factor in preeclampsia. Further studies are needed to confirm the association between hyperuricemia and outcomes of assisted reproductive technologies. Thus, ameliorating androgen excess with antiandrogenic drugs may benefit women with hyperandrogenism partly through decreasing the SUA level. Diane
35 treatments may help to cure hyperuricemia for PCOS women with hyperadrogenism [
15].
The strength of our study is its novelty and its large number of study subjects. However, several limitations should be taken into consideration. First, these subjects are infertility patients from our center. Therefore, our results may not be generalizable to the general population. Second, considering variations in uric acid secretion in different stages of the menstrual cycle, we measured the uric acid level only during the follicular phase. Third, our study was a retrospective study based on a single center, which may introduce selection bias. In addition, our results were restricted to Chinese women. Future studies in other populations are warranted to confirm our findings.